Poly(ethylene glycol)–avidin bioconjugates: suitable candidates for tumor pretargeting
- 18 September 2002
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 83 (1) , 97-108
- https://doi.org/10.1016/s0168-3659(02)00199-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot studyBritish Journal of Cancer, 2002
- Advances in pretargeting biotechnologyBiotechnology Advances, 2001
- Pre-Targeted Locoregional Radioimmunotherapy with 90Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic ResultsCancer Biotherapy & Radiopharmaceuticals, 2001
- Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotinEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicityBritish Journal of Cancer, 1998
- Stabilization of Substances in CirculationBioconjugate Chemistry, 1998
- The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Preservation of Thrombolytic Activity of Urokinase Modified with Monomethoxypoly(ethylene glycolJournal of Bioactive and Compatible Polymers, 1994
- The conjugation of proteins with polyethylene glycol and other polymersAdvanced Drug Delivery Reviews, 1993
- A method for the estimation of polyethylene glycol in plasma protein fractionsAnalytical Biochemistry, 1980